Application of nerolidol in preparing drug for treating fungal keratitis

A technology of fungal keratitis and nerolidol, which is applied in the pharmaceutical field, can solve the problems of patients with vision impairment, difficulty in restoring the cornea to transparency, and corneal tissue damage.

Inactive Publication Date: 2020-02-28
THE AFFILIATED HOSPITAL OF QINGDAO UNIV
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, an overly strong immune response can cause damage to the corneal tissue while controlling external infec

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of nerolidol in preparing drug for treating fungal keratitis
  • Application of nerolidol in preparing drug for treating fungal keratitis
  • Application of nerolidol in preparing drug for treating fungal keratitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Embodiment 1 Nerolidol inhibits the growth of Aspergillus fumigatus

[0032] 1. Experimental materials

[0033] 1.1 Experimental drugs: nerolidol (purchased from selleck company); Calcofluor fluorescent whitening agent (purchased from Sigma-aldrich company)

[0034] 1.2 Experimental fungi: 3.0772 strains of Aspergillus fumigatus (China Ordinary Microorganism Culture Collection Management Center)

[0035] 2. Experimental method

[0036] 2.1 Fungal preparation

[0037] The Aspergillus fumigatus strain was inoculated on Sabouraud medium, and cultured in a constant temperature incubator at 37°C for 2-3 days. Scrape the mycelia and conidia and put them into 5ml sterile PBS to form a mixed solution, filter the mycelium with sterile gauze. Centrifuge at 4500rpm at 4°C for 10 minutes, discard the supernatant, add 5ml PBS to the pellet to resuspend, and form a conidia suspension. Adjust the concentration of conidia to 5 x 10 with sterile PBS 6 cfu / ml.

[0038] 2.2 Minimum...

Embodiment 2

[0043] Example 2 Effects of nerolidol on corneal clinical score, neutrophil recruitment, and LOX-1 / IL-1β signaling pathway in fungal keratitis model mice.

[0044] 1. Experimental materials

[0045] 1.1 Experimental drug: nerolidol (purchased from selleck company)

[0046] 1.2 Experimental animals: C57BL / 6 mice (purchased from Jinan Pengyue Experimental Animal Breeding Co., Ltd.)

[0047] 1.3 Experimental fungus: 3.0772 strains of Aspergillus fumigatus (China Ordinary Microorganism Culture Collection Management Center)

[0048] 2. Experimental method

[0049] 2.1 Model mice

[0050] 8-week-old healthy and clean C57BL / 6 female mice were selected as research objects. Eye diseases were ruled out by slit lamp examination before the experiment, and the right eye was selected as the experimental eye. All operations on the experimental mice were in compliance with the regulations of the Ministry of Science and Technology of China on the humanized treatment of experimental animal...

Embodiment 3

[0063] Example 3 Nerolidol can prevent the LOX-1 / IL-1β pathway in fungal-stimulated human corneal epithelial cells

[0064] 1. Experimental materials

[0065] 1.1 Experimental drug: nerolidol (purchased from selleck company)

[0066] 1.2 Experimental cells: human corneal epithelial cells (purchased from the Ocular Surface Laboratory of Zhongshan Ophthalmology Center)

[0067] 1.3 Experimental fungus: 3.0772 strains of Aspergillus fumigatus (China Ordinary Microorganism Culture Collection Management Center)

[0068] 2. Experimental method

[0069] 2.1 Cell model experiments

[0070] Place human corneal epithelial cells at 37°C, 5% CO 2 in an incubator until the cell density reached 80%. The cells were divided into control group, PBS-treated fungal stimulation group, nerolidol-treated group, and nerolidol-treated fungal-stimulated group. Nerolidol (final concentration 200 μM) was added to the cell culture medium of the nerolidol treatment group and the fungal stimulation g...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the technical field of pharmacy and discloses application of nerolidol in preparing drug for treating fungal keratitis. It is put forward for the first time that nerolidol caninhibit fungus growth and has treatment effect on fungal keratitis in vivo and in vitro. In in-vivo experiments, C57BL/6 mice are adopted to build a fungal keratitis model to study impact of nerolidol on clinical scoring of model mouse cornea, neutrophil collection and human oxidized low-density lipoprotein receptor 1 and interleukin 1beta expression. In in-vitro experiments, inhibiting effect ofnerolidol at different concentrations on growth of aspergillus fumigatus is studied, and a human corneal epithelial cell model stimulated by aspergillus fumigatus is adopted to verify that nerolidolhas impact on LOX-1/IL-1beta signal pathway.

Description

technical field [0001] The invention belongs to the technical field of pharmacy, and in particular relates to the application of nerolidol in the preparation of medicines for treating fungal keratitis. Background technique [0002] Fungal keratitis (FK) is an infectious eye disease caused by pathogenic fungi, which can cause corneal ulcers and perforations. It is a corneal disease with high blindness and difficult treatment. Common pathogens include Fusarium and Aspergillus. In my country, ocular plant trauma is the main cause of disease, so plant-related Aspergillus fumigatus has become the most common pathogen in patients with fungal keratitis in my country. In clinical work, due to the untimely treatment of patients, and the shortcomings of common antifungal drugs such as poor water solubility and poor corneal penetration, the treatment effect is often poor, which leads to some patients developing corneal perforation and even blindness. Looking for a Safe and effective ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/045A61P31/10A61P27/02
CPCA61K31/045A61P27/02A61P31/10
Inventor 车成业杨桦
Owner THE AFFILIATED HOSPITAL OF QINGDAO UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap